94 Ces Urol 2023; 27(2): 86-94 PŘEHLEDOVÉ ČLÁNKY 29. Malmstrom TK, Morley JE. SARC‑F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. J Am Med Dir Assoc. 2013; 14(8): 531–2. 30. Ohtaka A, Aoki H, Nagata M, et al. Sarcopenia is a poor prognostic factor of castrationresistant prostate cancer treated with docetaxel therapy. Prostate Int. 2019; 7(1): 9–14. 31. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74–108. 32. Ibrahim A, Scher N, Williams G, et al. Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases. Clin Cancer Res. 2003; 9(7): 2394–9. 33. Katolická J. Bisfosfonáty u urologických malignit. Onkologie. 2013: 7(1): 18–21. 34. Sharma A, Sinha RJ, Singh V, et al. Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: a comprehensive review. Türk Ürol DergisiTurkish J Urol. 2019; 45(4): 245–53. 35. Shahinian VB, Goodwin JS. Risk of Fracture after Androgen Deprivation for Prostate Cancer. N Engl J Med. 2005; 352(2): 154–64. 36. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. The Journal of Urology. 2002; 168(3): 1005–1007. 37. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone‑Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8): 737–46. 38. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone ‑Sensitive Prostate Cancer: Long‑Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11): 1080–7. 39. Gravis G, Boher JM, Chen YH, et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG‑AFU15 Studies. Eur Urol. 2018; 73(6): 847– 55. 40. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4): 352–60. 41. Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). The Prostate. 2018; 78(12): 889–95.
RkJQdWJsaXNoZXIy NDA4Mjc=